Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
about
Tumor metastasis to boneHuman desmoid fibroblasts: matrix metalloproteinases, their inhibitors and modulation by ToremifeneChanges in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancerTargeting bone physiology for the treatment of metastatic prostate cancerMineral density volume gradients in normal and diseased human tissuesA novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancersActivation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cellsThe potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic targetProstate cancer in bone: importance of context for inhibition of matrix metalloproteinasesActivation of AMP-activated protein kinase by 3,3'-Diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivoDiosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expressionTumor-stromal interactions in bone metastasis.Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment.Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer.Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genisteinMatrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue.Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.Modulation of prostate cancer growth in bone microenvironments.Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.Hibiscus sabdariffa Leaf Extract Inhibits Human Prostate Cancer Cell Invasion via Down-Regulation of Akt/NF-kB/MMP-9 PathwayAssociation between MMP-2 expression and prostate cancer: A meta-analysisThe IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancerA role for endogenous reverse transcriptase in tumorigenesis and as a target in differentiating cancer therapy.Twist-related protein 1-mediated regulation of mesenchymal change contributes to the migration and invasion of cervical cancer cellsCombination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer.The role of the EGFR signaling in tumor microenvironment.ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasisBone marrow-derived cathepsin K cleaves SPARC in bone metastasis.Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis.Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases.MMP16 is a marker of poor prognosis in gastric cancer promoting proliferation and invasion.Assessment of the potential of pathological stains in human prostate cancer.
P2860
Q21195416-52EEBCC6-2313-4E04-89CC-6117E8D81B01Q24803335-8F69AE09-132E-4FD3-93EF-03BCC1B4644FQ24807354-E28189C0-8E88-42B0-90E8-2836B756F2E8Q26863249-20C9A755-419F-4B74-B9EA-4B4BE10540C1Q27310791-8DC3D5E5-3E53-4794-92FB-F32A568FB3B0Q27321296-509F8BFD-431F-43A3-97AA-294CEEFA4556Q27694500-68377DE0-FB64-48AD-B683-F97775D8DE8FQ28209528-6D538389-6BF8-4E15-8964-D33272E187AFQ28259937-358BA75E-28F8-4057-B11C-0EC6E4B8C26DQ28344383-5870CB4B-2779-4804-BFF3-10F7F8E3F8F5Q28484287-4F554D2B-48C0-492F-8C0E-331EFE49C99BQ33918409-3764E1EF-3D02-4D8F-8337-4EDD1F2ED8F4Q34022223-78D09F66-0CFE-47B0-83B0-93B5A1DF453BQ34057949-3C1748CC-5A5C-45D6-9B0F-37193F507F61Q34159609-1A36EFCB-1A21-451B-9B8E-9AF4B828638AQ34406622-CDE35953-F077-4862-B5CC-928CFA4DAA59Q34549787-2041AAA1-B488-4C44-942A-E0E7D6BC7557Q34768332-0082C0C9-EE9E-498E-B6DA-AB922E7BF5C5Q34770095-959A2946-247F-4D19-AFC4-CB6088E4497AQ35083825-49E54E6D-0702-415E-A656-7E996005C5A9Q35103092-2FC1721B-1A5A-47D6-8D83-E06E0D86B2B0Q35147059-9C15472A-B901-4A5B-AECF-56DB7441BE68Q35678554-63E38947-68D6-4779-A7E2-A7F8226331D7Q35855547-9B4CE3C7-5A0E-48FD-9869-A83D469B6F4BQ35894923-3910B5D5-BD3B-4970-A03A-64CB660512DAQ35928166-D3E08028-64EE-40B5-A642-584D56CD0C1AQ36062138-D7767933-17F1-4535-AB39-BE46E06F279CQ36263207-90C39B68-F221-4E8A-9C71-4F58416DF062Q36336372-CDE3DFC0-47B4-450F-9FCF-C9B75B84CB01Q36512574-1E99587A-35AB-475F-83D0-893F99FE6E0EQ36707418-E7169C5C-6A2F-4E60-A538-EC50CDA1C172Q36759374-E7D0EC20-B61E-42F9-A76C-D8923A776640Q36845839-9F48C297-830C-4BD8-9AA3-FBD66509E936Q36951215-0E0044DE-F8FE-4384-A36A-E6820B92412CQ37302910-B2D63A46-76DB-4CE3-AEB6-626DFF37E385Q37316559-1664B8B2-1452-48CB-BC77-72360302E6D0Q37350475-A3940DF0-29BC-4ADB-B013-FEE46D5B4A22Q37362838-5BF58991-BB1B-4230-AD1D-594422352E9DQ37588381-AA678FC8-E3C3-4543-AF1F-F6F119544BA6Q37611912-905E5F5C-E965-4DA2-B67D-814BC41C681E
P2860
Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Matrix metalloproteinase activ ...... ostate cancer bone metastasis.
@en
Matrix metalloproteinase activ ...... ostate cancer bone metastasis.
@nl
type
label
Matrix metalloproteinase activ ...... ostate cancer bone metastasis.
@en
Matrix metalloproteinase activ ...... ostate cancer bone metastasis.
@nl
prefLabel
Matrix metalloproteinase activ ...... ostate cancer bone metastasis.
@en
Matrix metalloproteinase activ ...... ostate cancer bone metastasis.
@nl
P2093
P356
P1476
Matrix metalloproteinase activ ...... ostate cancer bone metastasis.
@en
P2093
Bijan Shekarriz
Chadwick Mullins
Jeffrey A Nemeth
Jyoti Upadhyay
Michael Herzog
Michael L Cher
Mingxin Che
Rafael Fridman
Rafid Yousif
Sunita Bhagat
P356
10.1093/JNCI/94.1.17
P407
P577
2002-01-01T00:00:00Z